Currently, Lorlatinib is primarily used to treat non-small cell lung cancer in patients with ALK or ROS1 mutations. However, researchers are exploring its potential use in other types of cancer, including pediatric solid tumors and brain metastases. It is important to discuss treatment options with a healthcare provider to determine the most appropriate treatment plan for an individual's specific cancer type and stage.